| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 9.7 |
| Net income | -134.4 | -112.6 |
| EPS (diluted, $ a share) | $-1.28 | $-1.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -96.8% |
|---|
10-Q filed with the SEC, NASDAQ: BEAM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Beam Therapeutics Inc.: key numbers
- Share price
- $20.94Close, Nov 16
- Market cap
- $2.17B
- Shares outstanding
- 103.5MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Beam Therapeutics Inc.
All →Beam Therapeutics Financial Results
Beam Therapeutics reported third quarter 2026 financial results, ending the period with $1.0 billion in cash and marketable securities. The company highlighted clinical progress across its base editing portfolio, including an expected BLA submission for risto-cel in sickle cell disease as early as year-end 2026 and the anticipated completion of dosing for the BEAM-302 pivotal cohort in the first half of 2027.
- Term
- Q3 2026
“Our progress this quarter reflects the growing maturity and momentum of Beam’s platform, with predictable clinical translation across four distinct programs and multiple potentially transformative medicines advancing toward patients, bringing our vision for a new era of genetic medicine increasingly within reach.”
John Evans, chief executive officer of Beam Therapeutics
“We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027.”
John Evans, chief executive officer of Beam Therapeutics
Beam Therapeutics CEO John M. Evans Sells $1.19M of Stock
John M. Evans, CEO, sold 50,000 shares of Beam Therapeutics Inc. at $23.57 to $23.98 a share (average $23.77) in 2 transactions, worth $1.19M in total between Oct 15, 2026 and Oct 16, 2026. Shares held after the trade: 1,047,205 (-2.3%).
- Value
- $1.19M
- Shares
- 50,000
- Average price
- $23.77
- Role
- CEO
- Holding change
- -2.3%
- Trade date
- Oct 15, 2026 to Oct 16, 2026